Dimensions of HIV-related stigma in rural communities in Kenya and Uganda at the start of a large HIV 'test and treat' trial
- PMID: 33999961
- PMCID: PMC8128261
- DOI: 10.1371/journal.pone.0249462
Dimensions of HIV-related stigma in rural communities in Kenya and Uganda at the start of a large HIV 'test and treat' trial
Abstract
HIV-related stigma is a frequently cited barrier to HIV testing and care engagement. A nuanced understanding of HIV-related stigma is critical for developing stigma-reduction interventions to optimize HIV-related outcomes. This qualitative study documented HIV-related stigma across eight communities in east Africa during the baseline year of a large HIV test-and-treat trial (SEARCH, NCT: 01864603), prior to implementation of widespread community HIV testing campaigns and efforts to link individuals with HIV to care and treatment. Findings revealed experiences of enacted, internalized and anticipated stigma that were highly gendered, and more pronounced in communities with lower HIV prevalence; women, overwhelmingly, both held and were targets of stigmatizing attitudes about HIV. Past experiences with enacted stigma included acts of segregation, verbal discrimination, physical violence, humiliation and rejection. Narratives among women, in particular, revealed acute internalized stigma including feelings of worthlessness, shame, embarrassment, and these resulted in anxiety and depression, including suicidality among a small number of women. Anticipated stigma included fears of marital dissolution, verbal and physical abuse, gossip and public ridicule. Anticipated stigma was especially salient for women who held internalized stigma and who had experienced enacted stigma from their partners. Anticipated stigma led to care avoidance, care-seeking at remote facilities, and hiding of HIV medications. Interventions aimed at reducing individual and community-level forms of stigma may be needed to improve the lives of PLHIV and fully realize the promise of test-and-treat strategies.
Conflict of interest statement
Gilead Sciences provided tenofovir-emtricitabine (Truvada) in kind. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors do not have any other competing interest to declare.
References
-
- UNAIDS. Towards Universal Access: 2016–2021. Strategy: On the Fast-Track to end AIDS 2016.
-
- Chesney MA, Smith AW. Critical delays in HIV testing and care—The potential role of stigma. Am Behav Sci. 1999;42(7):1162–74. 10.1177/00027649921954822 WOS:000079414200006. - DOI
-
- Kulkarni S, Hoffman S, Gadisa T, Melaku Z, Fantehun M, Yigzaw M, et al.. Identifying Perceived Barriers along the HIV Care Continuum: Findings from Providers, Peer Educators, and Observations of Provider-Patient Interactions in Ethiopia. Journal of the International Association of Providers of AIDS Care. 2016;15(4):291–300. 10.1177/2325957415593635 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
